Table 11.

 Summary of treatment‐related AEs.

	Number (%) of patients
	Prophylactic use (n = 11)		Spontaneous use (n = 59)		Overall (n = 70)
	No. (%) of patients reporting AEs	No. of events	No. (%) of patients reporting AEs	No. of events	No. (%) of patients reporting AEs	No. of events
Total no.	1 (9%)	5	6 (10%)	17	7 (10%)	22
Type of AEs
Headache	1 (9%)	2	2 (3%)	5	3 (4%)	7
Vertigo	0 (0%)	0	2 (3%)	4	2 (3%)	4
Musculoskeletal stiffness	1 (9%)	3	0 (0%)	0	1 (1%)	3
Infusion site erythema	0 (0%)	0	2 (3%)	2	2 (3%)	2
Oedema peripheral	0 (0%)	0	1 (2%)	1	1 (1%)	1
Pyrexia	0 (0%)	0	1 (2%)	1	1 (1%)	1
Rigors	0 (0%)	0	1 (2%)	1	1 (1%)	1
Somnolence	0 (0%)	0	1 (2%)	1	1 (1%)	1
Contusion	0 (0%)	0	1 (2%)	1	1 (1%)	1
Pruritus generalized	0 (0%)	0	1 (2%)	1	1 (1%)	1

AE, adverse events.